AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03902743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticipatory Care Plan group
Description: The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
Study NCT05162950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: physical exercise as a standardized high intensity exercise test
Description: High intensity exercise test, cycling, performed at the Karolinska University Hospital
Study NCT05162950 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stress vulnerability
Description: Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
Study NCT02759341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Million Clinical Multiaxial Inventory 3 (MCMI-III)
Study NCT04492631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
Study NCT05477342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Board Game
Description: The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
Study NCT02753413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003891A
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT02753413 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT04464421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
Study NCT05477342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cesseation Education
Description: The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
Study NCT05477342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined İntervention
Description: The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale.
Study NCT05682820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements on knee MRI performed during routine clinical practice
Description: Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
Study NCT02691156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bilirubin Binding Capacity
Description: Research laboratory assay of bilirubin binding capacity
Study NCT02691156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: End-tidal Carbon Monoxide
Description: Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
Study NCT02691156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carboxyhemoglobin
Description: Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
Study NCT04622592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
Study NCT04622592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instramuscular vaccine
Description: On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
Study NCT04464421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Description: Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
Study NCT01664871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIammine SIlver Fluoride
Description: Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
Study NCT02338245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 400mg BID
Study NCT02338245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250mg QD
Study NCT02338245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Study NCT02338245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Study NCT02874118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fried scale for frailty assessement
Study NCT00785863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV before placebo infusion
Study NCT00785863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: placebo IV and remifentanil infusion
Study NCT00785863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac and remifentanil
Description: Ketorolac IV and remifentanil infusion
Study NCT00785863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib and remifentanil
Description: Parecoxib IV and remifentanil infusion
Study NCT01499134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
Study NCT01499134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
Study NCT00542113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DvtProgram ENERGY
Description: 11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
Study NCT00542113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DvtProgram ENERGY
Description: 6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
Study NCT00542113 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: DvtProgramENERGY
Description: Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
Study NCT05790408 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)
Description: The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
Study NCT05790408 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
Description: The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
Study NCT03996746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT03921450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Description: 1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
Study NCT03921450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: 50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
Study NCT03921450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Hz stimulation with the placebo TMS coil without any magnetic emission
Study NCT06552676 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous tracheostomy
Description: Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
Study NCT01067807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
Study NCT01067807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
Study NCT00530517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraject Sumatriptan
Description: needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
Study NCT00680342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 700mg dose (5 pills, three times daily) for 24-week treatment period
Study NCT00680342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 420mg dose (5 pills, three times daily) for 24-week treatment period
Study NCT00680342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (5 pills, three times daily) for 24-week treatment period
Study NCT02729701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duavee
Description: Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
Study NCT03329144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
Study NCT01771666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Elite Imaging
Description: A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
Study NCT01771666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%.
Study NCT02860533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cuff device
Description: Measurement of blood pressure during stress testing with cuff device
Study NCT02860533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iphone
Description: Measurement of blood pressure during stress testing with iPhone
Study NCT02759341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: State-Trait Anxiety Inventory form Y (STAI-Y)
Study NCT02759341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SF-36 Health-Related Quality of Life
Study NCT02759341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)
Study NCT01695096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Embryos will be cultured on a humidity free incubator
Description: We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
Study NCT01695096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The Embryos will be cultured on a >95% humidity incubator
Description: We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
Study NCT03135899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651
Description: Three doses, each 12 hours apart
Study NCT03135899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses, each 12 hours apart
Study NCT00946491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg Tablets (Cord Laboratories)
Study NCT00946491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haldol 10 mg Tablets (McNeil Pharmaceuticals)
Study NCT01877460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
Study NCT04052698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study NCT03404596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
Study NCT03404596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief counseling sessions, 10-15 minutes each.
Study NCT03404596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
Study NCT03404596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AutoSense
Description: Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Study NCT01078701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB11L1
Description: GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
Study NCT01078701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPGN buffer
Study NCT00588250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EmbryoGlue
Description: G2 culture media from Vitrolife which contains hyaluronic acid
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
Study NCT01067807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Proellex
Description: 25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab (Hu5F9-G4)
Description: Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Study NCT01067807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Proellex
Description: 50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Study NCT03721185 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dr.K. Treatment
Description: Overweight and obesity treatment response
Study NCT03721185 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Dr.K. Treatment
Description: Overweight and obesity treatment response
Study NCT03972358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All participants will receive 200 mg mifepristone, to be taken orally on day 1.
Study NCT03972358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Study NCT03869190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Study NCT02480426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-image guidance
Description: TIPS creation is performed under the guidance of 3D CT-image.